NMPA Greenlights Oricell Therapeutics’ OriCAR-017 for Clinical Trials in Multiple Myeloma
The National Medical Products Administration (NMPA) has indicated on its website that Oricell Therapeutics Co.,...
CAR-T
Poseida Therapeutics Secures $50 Million Investment from Astellas for Cell and Gene Therapy
US-based cell and gene therapy developer Poseida Therapeutics, Inc. (NASDAQ: PSTX) has announced a significant...
BRL Medicine Inc. Receives IND Approval for CD19-Targeted CAR-T Therapy BRL-301 from CDE
Shanghai-based BRL Medicine Inc. has announced that it has received Investigational New Drug (IND) approval...
GenScript Biotech’s CAR-T Therapy Carvykti Reports USD 117 Million in Sales
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...
Qihan Biotech’s QN-019a Receives Clinical Clearance for Gene-Edited iPSC-Derived Cell Therapy in China
Hangzhou Qihan Biotech Co., Ltd., a leading specialist in xenotransplantation based in China, has announced...
Hrain Biotechnology’s Anti-CD70 T Cell Therapy HR010 Gets Tacit Approval for Renal Cancer Trial
Shanghai-based Hrain Biotechnology Co., Ltd. has announced receiving tacit clinical trial approval from the Center...
Nanjing Kati Medical and Leman Biotech Partner to Advance Immune Metabolism Reprogramming in CAR-T Therapy
Nanjing Kati Medical Technology Co., Ltd, a China-based company, has entered into a partnership with...
Innovent Biologics and IASO Biotherapeutics’ Fucaso Approved for Multiple Myeloma Treatment in China
Innovent Biologics, Inc. (HKG: 1801) and IASO Biotherapeutics have announced that they have received marketing...
Fosun Kite’s Yescarta Gains NMPA Approval for Refractory Large B-Cell Lymphoma
China-based Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co.,...
Kite Pharma’s Yescarta Marketing Rights Transferred to Gilead Sciences K.K. in Japan
US immunotherapy specialist Kite Pharma, Inc. has announced that the Marketing Authorization for Yescarta (axicabtagene...
Shanghai Cell Therapy Group Partners with Nantong Federation for Comprehensive Health Services Platform
Shanghai Cell Therapy Group has entered into a partnership with the Nantong Federation of Industry...
Janssen Submits Additional Indication Application to FDA for Carvykti in Multiple Myeloma
The Janssen subsidiary of Johnson & Johnson (J&J; NYSE: JNJ) has submitted an additional indication...
Shanghai Fosun High Technology Partners with NICE for Joint Innovation Centers
China-based conglomerate Shanghai Fosun High Technology (Group) Co., Ltd has entered into a partnership with...
BioNTech’s DB-1303 ADC Shows Promising Results in Solid Tumor Phase I/IIa Trial
Germany’s BioNTech (NASDAQ: BNTX) has released preliminary data from a Phase I/IIa trial for DB-1303,...
Gilead’s Kite Announces Breakthrough Phase III Results for Yescarta in r/r LBCL
Gilead’s (NASDAQ: GILD) subsidiary Kite has published groundbreaking Phase III results for Yescarta (axicabtagene ciloleucel),...
Legend Biotech Submits sBLA to Expand Carvykti Label for Relapsed Multiple Myeloma
Legend Biotech Corporation (NASDAQ: LEGN) has announced the submission of a supplemental Biologics License Application...
Ucello Therapeutics Secures RMB 150 Million in Series A+ Financing for CAR-T Cell Therapy
Ucello Therapeutics, a developer of allogeneic universal chimeric antigen receptor (CAR)-T cell therapies based in...
GenScript’s Legend Biotech Files Type II Variation Application for Carvykti with EMA
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...
JW Therapeutics Secures Supply Agreement with Juno to Advance CAR-T Therapy Commercialization
China-based JW Therapeutics (HKG: 2126) has announced a carrier supply agreement with its shareholder Juno,...
Cabaletta Bio’s CABA-201 Clears FDA for Phase I/II Study in Idiopathic Inflammatory Myopathy
US-based Cabaletta Bio, Inc. (NASDAQ: CABA) has announced that the US Food and Drug Administration...